期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Th1 cytokine-based immunotherapy for cancer 被引量:4
1
作者 Hong-Mei Xu 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS 2014年第5期482-494,共13页
Cytokine-based immunotherapy is executed by harnessing cytokines to activate the immune system to suppress tumors. Th1-type cytokines including IL-1, IL-2, IL-12 and granulocyte-macrophage colony-stimulating factor ar... Cytokine-based immunotherapy is executed by harnessing cytokines to activate the immune system to suppress tumors. Th1-type cytokines including IL-1, IL-2, IL-12 and granulocyte-macrophage colony-stimulating factor are potent stimulators of Th1 differentiation and Th1-based antitumor response. Many preclinical studies demonstrated the antitumor effects of Th1 cytokines but their clinical efficacy is limited.Multiple factors influence the efficacy of immunotherapy for tumors. For instance immunosuppressive cells in the tumor microenvironment can produce inhibitory cytokines which suppress antitumor immune response. Most studies on cytokine immunotherapy focused on how to boost Th1 response; many studies combined cytokine-based therapy with other treatments to reverse immunosuppression in tumor microenvironment.In addition, cytokines have pleiotropic functions and some cytokines show paradoxical activities under different settings.Better understanding the physiological and pathological functions of cytokines helps clinicians to design Th1-based cancer therapy in clinical practice. 展开更多
关键词 cytokine gene therapy adjuvant therapy
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部